Screened 2026-09-08 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markup label.
Snowflake Inc. holds its Markup at $335.50. Consolidating, no directional conviction, held for 32 days.
As held on the ledger · 2026-09-08
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 32 days
Price at the screen
$335.50
Valuation
N/A trailing · 112.36 forward price to earnings
Values screen
PASS
Beta
1.33
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
4.59%
Below 33%
Interest-bearing debt is just 4.6% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
6.75%
Below 33%
Cash held in interest-bearing accounts and securities is 6.8% of assets, under the one-third limit.
Pass
Receivables
0.00%
Below 49%
Money owed to the company is 0.0% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-08 screen. The gold marker is the market price at the same screen. The price runs 23.2% above the base estimate.
Third-party analyst targets: 48 covering, consensus Strong Buy. The average target sits +31% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-08 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Snowflake's Price Chill in a Hot Market
Imagine a winter morning where ice forms on a window pane, each frost pattern unique and intricate, much like Snowflake’s data architecture. Snowflake Inc. stands out in a crowded tech space with its cloud-based data warehousing solution, a service that thrives amidst the exponential data growth. With revenue growth of 34%, the company is capitalizing on the digital transformation wave, offering businesses the ability to store and analyze data at scale.
However, the company's forward P/E of 118.7x is frosty, even for a tech stock. This high valuation, paired with a negative profit margin of -24% and ROE of -55%, suggests a company heavily reliant on market optimism and future growth projections. While Snowflake's ethical screen passed, the market's consensus rating of 'buy' and a median target price of $320 align with its current price, implying little margin of safety.
Risks are manifold, with a weak moat indicating a lack of competitive advantage, and the stock’s value heavily contingent on continued rapid growth and market acceptance of its high valuation. As with any tech stock in a frothy market, there's the risk of a sudden market correction which could crystallize the true value of Snowflake's shares.
The risks · The things to watch: it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
SNOW trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-02Accumulation$321.29+0.0%Entry 12
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (48 analysts) rates it buy, with a mean price target of $230. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-09-01Accumulation$321.29+0.0%Entry 11
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (48 analysts) rates it buy, with a mean price target of $230. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-31Accumulation$321.29+0.0%Entry 10
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (48 analysts) rates it buy, with a mean price target of $230. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-30Accumulation$321.29+0.0%Entry 9
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (48 analysts) rates it buy, with a mean price target of $230. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-29Accumulation$321.29+0.0%Entry 8
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (48 analysts) rates it buy, with a mean price target of $230. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-28Accumulation$321.29+0.0%Entry 7
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (48 analysts) rates it buy, with a mean price target of $230. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-27Accumulation$321.29+0.0%Entry 6
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (48 analysts) rates it buy, with a mean price target of $230. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.4% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (48 analysts) rates it buy, with a mean price target of $230. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-13Markup$316.84+33.0%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 33.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (48 analysts) rates it buy, with a mean price target of $230. Insiders have been net sellers over the past quarter.
2026-07-18Markup$238.26+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 15%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (48 analysts) rates it buy, with a mean price target of $230. Insiders have been net sellers over the past quarter.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
